NCT00654836 - Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 29, 2012

Study Completion Date

September 30, 2015

Conditions

Breast Cancer

Interventions

BIOLOGICAL

bevacizumab

Participants will receive bevacizumab 15 mg/kg on days 1,22, and 43.

DRUG

Carboplatin

Participants will receive a standard carboplatin dose according to their area under the plasma drug concentration-time curve (AUC-6) on days 1, 22, and 43.

DRUG

ABI-007

Participants will receive ABI-007 (Abraxane) 100mg/m2 on days 1,8, 15, 22, 29, 36,43,and 50.

Trial Locations (6)

60153

Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood

60540

Edward Hospital Cancer Center, Naperville

60515-1500

Good Samaritan Cancer Care Center at Advocate Good Samaritan Hospital, Downers Grove

60134-4200

Delnor Community Hospital - Geneva, Geneva

61104-2315

Swedish-American Regional Cancer Center, Rockford

60190-1295

Central Dupage Cancer Center, Winfield